Regulators have cleared the company’s manufacturing partner to sell its Chinese-labelled infant formula in China,one of A2’s key growth markets.
This time last year,the infant formula maker’s chief executive Kristy Carr was beaming after being personally thanked by US President Joe Biden for bringing her product to the US.
The $4.3 billion milk and infant formula giant has engineered a commendable turnaround since COVID-19 – but are investors pleased?
The health of women and children are being sold to the highest bidder as baby formula manufacturers rake in $US55 billion a year.
The infant formula maker has managed to ride out the harsh zero-COVID lockdowns imposed on its most lucrative market,but investors are not impressed.
Dairy giant A2 Milk has been given the green light to export its infant formula to the US,more than five months after its smaller rival Bubs Australia was given approval.
ASX-listed infant formula maker will make and sell locally made product to Chinese parents through a new joint venture that opens the door to a lucrative $40 billion market.
A2 Milk’s shares have jumped after its Chinese-label baby formula producer received approval to continue manufacturing product until late February.
Infant formula maker Bubs Australia wants to establish brand loyalty from parents in the world’s two biggest economies as it pursues growth,but Australia will not be left out.
A2 Milk has had its approval to import baby formula to the US deferred as it seeks to chase smaller Australian competitors in the market.
Bubs Australia is looking forward to a long future in the US market while it prepares to load a fifth and sixth plane of infant formula products for delivery.